WVE
Wave Life Sciences Ltd.
There isn't enough reported data to score WVE yet.
WVE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
WVE's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
WVE PE Valuation
WVE has no meaningful PE right now: it lost money over the past year.
WVE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect WVE's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
WVE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.06 | -$0.40 |
| Q2 2026 | -$1.08 | -$0.27 |
| Q1 2026 | -$1.05 | -$0.30 |
| Q4 2025 | -$1.21 | -$0.51 |
| Q3 2025 | -$0.66 | +$0.44 |
| Q2 2025 | -$0.81 | -$0.25 |
| Q1 2025 | -$0.75 | -$0.24 |
| Q4 2024 | -$0.70 | -$0.16 |
WVE is still losing money, but far less than before: $1.06 per share over the past year, against $5.73 at its worst in early 2020.
WVE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.3M | -74% |
| Q1 2026 | $38.2M | +317% |
| Q2 2025 | $8.7M | -56% |
| Q1 2025 | $9.2M | -27% |
| Q2 2024 | $19.7M | -11% |
| Q1 2024 | $12.5M | -3% |
| Q4 2023 | $29.1M | +2245% |
| Q3 2023 | $49.2M | +17168% |
WVE's revenue is recovering but still below its 2023 peak: $13M last quarter, up 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -502% | N/A |
| Q2 2026 | -3248% | -2642 points |
| Q1 2026 | -82% | +461 points |
| Q2 2025 | -606% | -429 points |
| Q1 2025 | -543% | -268 points |
| Q2 2024 | -178% | -72 points |
| Q1 2024 | -275% | -41 points |
| Q4 2023 | -64% | +3452 points |
WVE's operating margin was −502% last quarter, up 41 points from the same quarter a year ago.
WVE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$60.2M | -$15.2M |
| Q2 2026 | -$54.5M | -$8.1M |
| Q1 2026 | -$60M | +$3.2M |
| Q4 2025 | -$33.8M | +$10M |
| Q3 2025 | -$44.9M | +$1.9M |
| Q2 2025 | -$46.3M | -$18.8M |
| Q1 2025 | -$63.2M | -$29.4M |
| Q4 2024 | -$43.7M | -$10.1M |
WVE has burned cash in almost every quarter: −$208M over the past year, against −$198M the year before.
WVE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +214K shares |
| 1 year | +22% | +36.5M shares |
| 3 years | +91% | +97.2M shares |
| 5 years | +303% | +154M shares |
| Available history | +503% | +170M shares |
WVE has 204M diluted shares, up 22% from a year ago.
WVE Net Leverage
WVE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
WVE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.2 | Oversold |
| Stochastic | 9.8 | Oversold |
WVE's weekly RSI is 29 (oversold) and its Stochastic is 10 (oversold).
WVE PE vs Healthcare Sector
WVE has no meaningful PE right now: it lost money over the past year.
WVE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.43 | 8.2% below |
| 20 week MA | $4.64 | 32% below |
| 50 week MA | $8.10 | 61% below |
| 100 week MA | $8.32 | 62% below |
| 200 week MA | $7.13 | 56% below |
WVE is in a downtrend: it's below all five of its weekly moving averages, and 56% below its 200-week average.
WVE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.8 | $8.91 | -44% |
| 2021 | $8.91 | $3.70 | -58% |
| 2022 | $3.70 | $6.51 | +76% |
| 2023 | $6.51 | $5.05 | -22% |
| 2024 | $5.05 | $12.9 | +155% |
| 2025 | $12.9 | $17.8 | +38% |
| 2026 YTD | $17.8 | $3.15 | -82% |
WVE's yearly returns have swung widely, from +155% in 2024 to −58% in 2021. It's down 82% so far in 2026.